2,3,5-三-O-苄基-D-阿拉伯呋喃糖-1-(4-硝基苯甲酸酯) | 52522-49-3

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3,5-三-O-苄基-D-阿拉伯呋喃糖-1-(4-硝基苯甲酸酯)
• 中文别名: 1-对硝基苯甲酸-2,3,5-三苄氧基-D-阿拉伯呋喃糖甙；1-对硝基苯甲酸-2,3,5-三苄氧基-D-阿拉伯呋喃糖苷；2,3,5-三-氧-苄基-1-氧-对硝基苯甲酰基-D-阿拉伯呋喃糖苷；2,3,5-三-O-苄基-1-O-对硝基苯甲酰基-D-阿拉伯呋喃糖；ARA D-糖；2,3,5-三-苄基氯-1-硝基苯甲酰-D-阿拉伯呋喃糖苷
• 英文名称: 2,3,5-tri-O-benzyl-1-(4-nitrobenzoyloxy)-D-arabinofuranose
• 英文别名: 2,3,5-tri-O-benzyl-1-O-(4-nitrobenzoyl)-D-arabinofuranose；2,3,5-tri-O-benzyl-1-O-(p-nitrobenzoyl)-D-arabinofuranose；2,3,5-tri-O-benzyl-1-O-p-nitrobenzoyl-D-arabinofuranose；2,3,5-tri-O-benzyl-1-O-p-nitrobenzoyl-D-arabinose；2,3,5-tri-O-benzyl-1-O-(4-nitro-benzoyl)-D-arabinofuranose；1-O-(4-nitrobenzoyl)-2,3,5-tri-O-benzyl-D-arabinofuranose；[(3S,4R,5R)-3,4-bis(phenylmethoxy)-5-(phenylmethoxymethyl)oxolan-2-yl] 4-nitrobenzoate
• CAS: 52522-49-3
• 化学式: C₃₃H₃₁NO₈
• mdl: MFCD00038477
• 分子量: 569.611
• InChiKey: VBDBDZHLJKDSSB-UFRUDBOASA-N

物化性质

• 熔点：
  86-88 °C(lit.)
• 沸点：
  633.08°C (rough estimate)
• 密度：
  1.2620 (rough estimate)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，未有已知危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  42
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.242
• 拓扑面积：
  109
• 氢给体数：
  0
• 氢受体数：
  8

安全信息

• 安全说明：
  S24/25
• WGK Germany：
  3
• 海关编码：
  29400090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  密封，在-20°C下保存

SDS

Name:	2 3 5-Tri-O-benzyl-1-O-(4-Nitrobenzoyl)-D-Arabinofuranose 97% Material Safety Data Sheet
Synonym:	None
CAS:	52522-49-3

Section 1 - Chemical Product MSDS Name:2 3 5-Tri-O-benzyl-1-O-(4-Nitrobenzoyl)-D-Arabinofuranose 97% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
52522-49-3	2,3,5-Tri-O-benzyl-1-O-(4-Nitrobenzoyl	97%	257-992-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 52522-49-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: off-white powder
Odor: odorless
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 69-72C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C33H31NO8
Molecular Weight: 569.2189

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 52522-49-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,3,5-Tri-O-benzyl-1-O-(4-Nitrobenzoyl)-D-Arabinofuranose - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 52522-49-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 52522-49-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 52522-49-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3,5-三-O-苄基-D-阿拉伯呋喃糖-1-(4-硝基苯甲酸酯) 在 盐酸 、 氨 、 三氯化硼 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 8.17h， 生成 阿糖腺苷
  参考文献：
  名称：

  Kadir, Kamaliah; Mackenzie, Grahame; Shaw, Gordon, Journal of the Chemical Society. Perkin transactions I, 1980, p. 2304 - 2309

  摘要：

  DOI：
• 作为产物：
  描述：

  2,3,5-tri-O-benzyl-D-arabinose 、 4-硝基苯甲酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 以44 g的产率得到2,3,5-三-O-苄基-D-阿拉伯呋喃糖-1-(4-硝基苯甲酸酯)
  参考文献：
  名称：

  Kadir, Kamaliah; Mackenzie, Grahame; Shaw, Gordon, Journal of the Chemical Society. Perkin transactions I, 1980, p. 2304 - 2309

  摘要：

  DOI：

文献信息

• Synthesis and pharmacological evaluation of a series of analogs of 1-methylisoguanosine
  作者：Robert T. Bartlett、Alan F. Cook、Michael J. Holman、Warren W. McComas、Eugene F. Nowoswait、Mohindar S. Poonian、Judy A. Baird-Lambert、Brian A. Baldo、John F. Marwood

  DOI：10.1021/jm00140a007

  日期：1981.8

  Modification at the 5' position yielded the deoxy, iodo, and phosphate derivatives 15, 13, and 16, as well as the cyclic 3',5'-phosphate 17. The synthesis of the C-nucleoside analogue 19 was achieved from the beta-D-ribofuranosylcarboximidic ester 20. The acyclic analogue 29 and the beta-D-arabinofuranosyl derivative 35 were both synthesized by reaction of methyl isocyanate with the appropriately protected

  在肌肉松弛剂，心血管，抗炎和抗过敏试验中，评估了具有药理活性的海洋天然产物1-甲基异鸟苷（1）的一系列类似物的生物活性。在1位上的修饰分别产生乙基，正丁基，正辛基和苯基衍生物3-6。在8位的取代提供了溴，肼和氨基化合物9-11。在5'位的修饰产生了脱氧，碘和磷酸盐衍生物15、13和16，以及环状3'，5'-磷酸盐17。C-核苷类似物19的合成由β完成-D-呋喃核糖基羧酰亚胺酯20。无环类似物29和β-D-阿拉伯呋喃糖基衍生物35都是通过异氰酸甲酯与适当保护的氨基氰咪唑前体28和32反应合成的。1-甲基黄嘌呤（12），异鸟苷（7）和2-甲氧基腺苷（18）。也被合成。在高达100 mg / kg po的剂量下，5'-磷酸16，环状3'，5'-磷酸17和O-甲基化的类似物2-甲氧基腺苷18在产生肌肉松弛和体温过低方面具有活性。这些化合物具有抗过敏活性，并且与1-乙基（3）和1-正丁基（4）类似物
• D-Arbinose-Based Synthesis of homo-<i>C</i>-d4T and homo-<i>C</i>-thymidine
  作者：Bogdan Doboszewski

  DOI：10.1080/15257770903306518

  日期：2009.10.28

  2,5-anhydro-4,6-di-O-benzoyl-3-deoxy-D-ribo-hexitol, which were coupled with N-3-benzoylthymine under the Mitsunobu conditions to furnish two analogs of nucleosides with a -CH2- insert between sugar moieties and thymine. D-Arbinose-Based Synthesis of homo-C-d4T and homo-C-thymidineAll authorsBogdan Doboszewskihttps://doi.org/10.1080/15257770903306518 Published online:20 October 2009

  使2,3,5-Tri- O-苄基-D-阿拉伯呋喃糖基卤化物（氯化物，溴化物）与AllMgBr，MeMgBr和VinMgBr反应，以提供C-糖基产物的异头混合物。讨论了影响β/α比的因素。将α，β- C-乙烯基衍生物转化为1-脱氧-1- C-羟甲基-β-和-α-D-阿拉伯呋喃糖酶（分别为2,5-脱水-D-葡萄糖醇和-甘露醇），可在分离后分离异丙基化步骤。2,5-脱水-1,3- O-异亚丙基-D-葡萄糖醇被转化为2,5-脱水-6- O-三苯甲基-D-赤型-hex-3,4-烯醇和2,5-脱水- 4,6-二-O-苯甲酰基-3-脱氧-D-核糖-己糖醇，在Mitsunobu条件下与N-3-苯甲酰胸腺嘧啶偶联，以提供两个在糖基团和胸腺嘧啶之间插入-CH 2-的核苷类似物。 的d-Arbinose基于合成均聚物Ç -d4T和均聚Ç -胸苷所有作者Bogdan Doboszewski https://doi
• Dye-Sensitized Photooxygenation of Furanosyl Furans:  Synthesis of a New Pyridazine <i>C</i>-Nucleoside
  作者：Flavio Cermola、M. Rosaria Iesce、Gianluca Buonerba

  DOI：10.1021/jo0504159

  日期：2005.8.1

  The dye-sensitized photooxygenation of furanosyl furans easily affords C- or O-glycosides with cis-α,β-unsaturated 1,4-dioxo aglycones. The reaction, performed on a ribofuranosyl furan, provides a useful new entry to a novel pyridazine C-nucleoside that can be achieved through a simple one-pot procedure.

  呋喃糖基呋喃的染料敏化光氧化，得到易于C-或O-与顺苷- α，β -不饱和的1,4-二氧代糖苷配基。在呋喃核糖基呋喃核糖核酸上进行的反应为新型哒嗪C-核苷提供了一个有用的新入口，可以通过简单的一锅法实现。
• Polysubstituted benzimidazoles as antiviral agents
  申请人：The Regents of the University of Michigan

  公开号：US05574058A1

  公开（公告）日：1996-11-12

  Polysubstituted benzimidazoles and pharmaceutical compositions containing them as the active ingredients. These compounds and compositions exhibit antiviral activity against viruse of the herpes family, particularly human cytomegalovirus and herpes simplex viruses (HSV).

  多取代苯并咪唑及含有其作为活性成分的药物组合物。这些化合物和组合物对疱疹病毒家族的病毒，特别是人类巨细胞病毒和单纯疱疹病毒（HSV）表现出抗病毒活性。
• Novel nucleosides and related processes, pharmaceutical compositions and methods
  申请人：——

  公开号：US20040116362A1

  公开（公告）日：2004-06-17

  The invention provides novel nucleosides and related processes, pharmaceutical compositions, and methods. The novel nucleosides are useful in a wide variety of antiviral, antineoplastic, and antibacterial applications. Preferred embodiments of the instant invention include novel 2 halogen-substituted, 3 halogen-substituted, and 2′,3′dihalogen-substituted analogues of 3-deazaadenosine, and novel 3 halogen-substituted analogues of 3-deazaguanosine. Compounds of the instant invention, including 4-Amino-6-fluoro-1-(&bgr;-D-ribofuranosyl)imidazo[4,5-c]pyridine and 6-Amino-7-bromo-1,5-dihydro-1-&bgr;- D -ribofuranosylimidazo[4,5-c]pyridin-4-one, have exhibited potent antiviral and anticancer activity in vitro. The compounds are also useful in the concomitant treatment of bacterial infections associated with viral infections such as AIDS.

  该发明提供了新颖的核苷和相关的工艺、药物组合和方法。这些新颖的核苷在抗病毒、抗肿瘤和抗菌应用中非常有用。该发明的首选实施例包括新型的2卤代、3卤代和2′,3′二卤代的3-去氨腺苷类似物，以及新型的3卤代的3-去氨鸟苷类似物。该发明的化合物，包括4-氨基-6-氟-1-(&bgr;-D-核糖呋喃基)咪唑[4,5-c]吡啶和6-氨基-7-溴-1,5-二氢-1-&bgr;-D-核糖基咪唑[4,5-c]吡啶-4-酮，在体外表现出强效的抗病毒和抗癌活性。这些化合物也在同时治疗与艾滋病等病毒感染相关的细菌感染方面非常有用。